Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) generates frequent news flow around its work in hereditary angioedema (HAE) and the commercialization of EKTERLY (sebetralstat). Company press releases highlight regulatory approvals, commercial launches, clinical data presentations and financial updates tied to this first and only oral on-demand treatment for acute HAE attacks in people 12 years of age and older.
News items cover major milestones such as FDA approval of EKTERLY in the United States, subsequent approvals in the European Union, United Kingdom, Switzerland, Australia, Singapore and Japan, and the initiation of commercial launches in the U.S. and Germany. KalVista also reports on licensing and commercialization agreements with partners like Kaken Pharmaceutical in Japan, Pendopharm in Canada and Multicare Pharmaceuticals in Latin America, which expand EKTERLY’s reach into additional markets.
Investors and clinicians following KALV can track updates on net product revenue from EKTERLY, patient start forms, prescriber activation and refill trends, as well as financing events such as the issuance of convertible senior notes. The company regularly announces new clinical and real‑world data from the KONFIDENT, KONFIDENT‑S and KONFIDENT‑KID studies, including patient satisfaction, pediatric interim results and European experience with sebetralstat, often presented at meetings such as the American College of Allergy, Asthma & Immunology Annual Scientific Meeting and the German Allergy Congress.
Additional KalVista news includes corporate governance developments, board and executive appointments, inducement equity grants and participation in healthcare investor conferences. This news page allows readers to follow how KalVista advances EKTERLY globally, engages with the HAE community and reports on its operational and financial progress over time.
KalVista Pharmaceuticals (NASDAQ: KALV) announced its participation in a fireside chat at the Jefferies Global Healthcare Conference. The presentation is scheduled for Thursday, June 5, 2025, at 8:45 a.m. ET. Investors and interested parties can access a live webcast of the presentation through KalVista's website at www.kalvista.com. The audio recording will remain available on the company's website for 30 days following the presentation.
KalVista Pharmaceuticals (NASDAQ: KALV) has announced its upcoming participation in a fireside chat at the Citizens Life Sciences Conference. The presentation is scheduled for Wednesday, May 7, 2025, at 11:30 a.m. ET.
Interested parties can access a live webcast of the presentation through KalVista's website at www.kalvista.com. For those unable to attend the live session, an audio recording will remain accessible on the company's website for 30 days following the presentation.
KalVista Pharmaceuticals (Nasdaq: KALV) has entered into a licensing agreement with Kaken Pharmaceutical for commercialization rights of sebetralstat in Japan. The deal includes an $11 million upfront payment, potential additional payment of up to $11 million upon achieving regulatory milestone expected in early 2026, plus commercial milestone payments and royalties approximately in the mid-twenties percentage of sales.
Sebetralstat is an investigational, oral on-demand treatment for hereditary angioedema (HAE). The drug has received Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare, and KalVista has submitted a New Drug Application in Japan. If approved, sebetralstat would become the first oral on-demand treatment for HAE in Japan.
KalVista Pharmaceuticals (NASDAQ: KALV) has granted inducement stock options to ten newly-hired employees. The aggregate grant consists of 87,000 shares of KalVista common stock, issued on April 1, 2025.
The options' exercise price matches KalVista's common stock closing price on the grant date. The vesting schedule includes 25% after one year, with the remaining vesting monthly over three years, contingent on continued employment. The options have a 10-year term and fall under KalVista's Inducement Equity Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company will engage in a fireside chat scheduled for Monday, April 7, 2025, at 1:30 p.m. ET.
The presentation will be accessible through a live webcast on KalVista's official website. Additionally, an audio recording of the presentation will remain available on the company's website for 30 days following the event.
KalVista Pharmaceuticals (KALV) has completed enrollment for its KONFIDENT-KID clinical trial of sebetralstat, an oral plasma kallikrein inhibitor for pediatric hereditary angioedema (HAE) patients aged 2-11. Due to high demand, the trial expanded from 24 to approximately 36 patients across seven countries in North America, Europe, and Asia.
The enrollment was completed a full year ahead of schedule. The trial will collect safety, pharmacokinetic, and efficacy data for up to one year using a proprietary pediatric oral disintegrating tablet formulation. Initial results are expected before year-end, with an sNDA submission planned by mid-2026.
If approved, sebetralstat would become the first oral on-demand therapy for pediatric HAE patients aged 2-11 years and only the second FDA-approved on-demand treatment in this population. Currently, the only available on-demand treatment for this age group in the U.S. requires intravenous administration.
KalVista Pharmaceuticals (KALV) reported its Q3 fiscal 2025 results and operational updates, highlighting significant progress for sebetralstat, its oral treatment for hereditary angioedema (HAE). The company secured its seventh regulatory submission and orphan drug designation in Japan, with FDA PDUFA date set for June 17, 2025.
New clinical data demonstrated sebetralstat's effectiveness in treating laryngeal attacks, with median symptom relief time of 1 hour 16 minutes. The drug showed promise for adolescents and patients on long-term prophylaxis, who experienced 1.7 HAE attacks per month with symptom relief in 1.3 hours median time.
Financially, KalVista reported no revenue for Q3. R&D expenses decreased to $12.6M from $22.5M year-over-year, while G&A expenses increased to $30.3M from $10.6M due to pre-commercial activities. The company secured $160M through royalty financing and equity offerings, maintaining a strong cash position of $253.2M as of January 31, 2025.
KalVista Pharmaceuticals (NASDAQ: KALV) has announced a virtual investor event focused on the commercialization strategy for sebetralstat, their investigational treatment for hereditary angioedema (HAE).
The webcast is scheduled for Tuesday, March 25, 2025, from 8:00 AM to 10:00 AM ET. The event will feature presentations from KalVista's management team and leading HAE experts who will discuss:
- Current HAE treatment guidelines
- Unmet needs for HAE patients
- Potential of sebetralstat as a new treatment option
The event will include a live Q&A session and can be accessed through the Investors section at ir.kalvista.com. A replay will be available after the event.